Recombinant Anti-IL13 x Anti-IL17 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-IL13 and anti-IL17 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can bind and inactivate two ligands simultaneously. It is designed for the research of Asthma therapy.
There are currently no customer reviews or questions for Recombinant Human Anti-IL13 x Human Anti-IL17 Bispecific Antibody (scIgG) (SCIGG-H337). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS